Technical analysis of Atea Pharmaceuticals, Inc. (AVIR): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Price Performance
| 1 month | -2.46% |
| 3 months | +18.12% |
| Year-to-date | +44.26% |
| 1 year | +76.98% |
| 3 years | +61.95% |
| 5 years | -80.37% |
52-Week Range
| 52-week High | $6.45 |
| 52-week Low | $2.78 |
| Avg Volume (90d) | 329K |
Technical Indicators
| SMA 50 | $5.10 |
| SMA 200 | $4.69 |
| Beta | 0.16 |
| 30-day Volatility (annualised) | 44.9% |
| Price vs SMA 50 | +1.0% |
| Price vs SMA 200 | +9.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $3.25 | |
| 2025-11 | $3.10 | -4.6% |
| 2025-12 | $3.57 | +15.2% |
| 2026-01 | $4.24 | +18.8% |
| 2026-02 | $4.68 | +10.4% |
| 2026-03 | $5.38 | +15.0% |
| 2026-04 | $5.51 | +2.4% |
| 2026-05 | $4.67 | -15.2% |
| 2026-06 | $4.65 | -0.4% |
| 2026-07 | $4.70 | +1.1% |
| 2026-08 | $5.35 | +13.8% |
| 2026-09 | $5.15 | -3.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $5.15 |
| Market Cap | $412M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.84 |
| EV / EBITDA | -2.04 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 8.13 |